Table 6.

Model 3: Relative incidence of adverse events of interest and interaction term for vaccine type in adults aged 18 to 64 years.

	RI	95% CI	p
Exposure risk period (with date of vaccination as day 0)
Days 0 to 6	2.84	2.63–3.06	<0.001
Time from start of influenza season (reference: Days 0 to 29)
Days 30 to 59	0.97	0.94–0.99	0.006
Days 60 to 89	0.98	0.95–1.00	0.069
Days 90 to 119	0.83	0.81–0.85	<0.001
Days 120 to 149	1.07	1.04–1.10	<0.001
Days 150 to 179	1.05	1.02–1.07	<0.001
Days 180 to 209	0.88	0.86–0.90	<0.001
Days 210 to 241	0.59	0.57–0.60	<0.001
Vaccination type (reference: QIVc)
QIVe	0.84	0.78–0.91	<0.001

Note. QIVc: cell culture-based quadrivalent influenza vaccine; QIVe: egg-based quadrivalent influenza vaccine.